


GXH-II-052

Cat. No.:	HY-150684
Molecular Formula:	C ₆₂ H ₇₆ Cl ₂ F ₂ N ₁₄ O ₁₁ S ₂
Molecular Weight:	1366.39
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K _d values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc ^[1] .																			
IC₅₀ & Target	BRD4-1 28 nM (Kd)	BRD4-2 9.1 nM (Kd)	BRD4-T 4.8 nM (Kd)	BRDT-1 0.6 nM (Kd)																
	BRDT-2 8.4 nM (Kd)	BRDT-T 2.6 nM (Kd)																		
In Vitro	<p>GXH-II-052 (0-10 μM; 72 h) shows antiproliferative activity with an IC₅₀ value of 59 nM in MM1.S cells^[1]. GXH-II-052 (0-10 μM; 6 h) decreases the expression of c-Myc in a dose dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MM1.S cells</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Showed growth inhibition with an IC₅₀ value of 59 nM in multiple myeloma MM1.S cells.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MM1.S cells</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the expression of c-Myc in a dose dependent manner.</td> </tr> </table>				Cell Line:	MM1.S cells	Concentration:	0-10 μM	Incubation Time:	72 h	Result:	Showed growth inhibition with an IC ₅₀ value of 59 nM in multiple myeloma MM1.S cells.	Cell Line:	MM1.S cells	Concentration:	0-10 μM	Incubation Time:	6 h	Result:	Decreased the expression of c-Myc in a dose dependent manner.
Cell Line:	MM1.S cells																			
Concentration:	0-10 μM																			
Incubation Time:	72 h																			
Result:	Showed growth inhibition with an IC ₅₀ value of 59 nM in multiple myeloma MM1.S cells.																			
Cell Line:	MM1.S cells																			
Concentration:	0-10 μM																			
Incubation Time:	6 h																			
Result:	Decreased the expression of c-Myc in a dose dependent manner.																			
In Vivo	GXH-II-052 shows metabolic stability in mouse and human liver microsomes with an T _{1/2} values of 33, 3.6 min, respectively ^[1] .																			

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Guan X, et al. Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. J Med Chem. 2022 Jul 22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA